Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study

Go back to Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study
(NASDAQ: EDSA) Delayed: 2.76 -0.09 (3.16%)
Previous Close $2.85    52 Week High $ 
Open $2.89    52 Week Low $ 
Day High $2.99    P/E N/A 
Day Low $2.75    EPS $ 
Volume 22,690